CD8A and carcinoma: In carcinomas, tumor cell neo-antigens presented by cross-presenting classical DCs (cDC1 subset) on MHC-I to the cognate TCR of CD8+ T cells elicit among the strongest anti-tumor adaptive immune responses (115).